A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on Fluzoparib
A Single Center, Single Arm, Open and Fixed Sequence Study to Investigate the Pharmacokinetic Effects of Rifampicin on Fluzoparib in Healthy Male Subjects
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
A PHASE1 clinical study on Healthy Male Subjects, this trial is completed. The trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and has accumulated 6 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE1
Status: Not Yet Recruiting → Active Not Recruiting
▶ Show 1 earlier version
-
Aug 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu HengRui Medicine Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .